12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cortiment budesonide MMX regulatory update

Cosmo said the Netherlands Medicines Evaluation Board (MEB) decided not to approve an MAA for Cortiment budesonide to treat active, mild to moderate ulcerative colitis. Cosmo said MEB based its decision on "clinical relevance," but the company...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >